Tumor blood vessels are essential for tumor growth. Therefore, these blood vessels are potential targets for anticancer therapy. The purpose of this study is to develop anti-tumor endothelial cell (TEC) antibodies for delivering anticancer agents or drugs. To achieve this goal, we utilized the phage antibody display library method to create monoclonal antibodies in vitro. Accordingly, we developed anti-TEC antibodies from an single chain Fv fragment (scFv) phage display library prepared using the Fv genes ampliˆed from the mRNAs isolated from the TEC-immunized mice. The size of the phage antibody library prepared from the mRNA of the TEC-immunized mice was approximately 1.3×10 7 CFU. To select and enrich for the phages displaying the anti-TEC antibodies, cell panning was performedˆrst using the TEC followed by subtractive panning using the normal endothelial cell. Afterˆve cycles of panning, the a‹nity of bound phage clones increased approximately 10 000 folds. Subsequently, clones isolated from the post-panning output library were tested for their antigen-speciˆcity by ELISA and western blotting. One of the scFv phage clones showing antigenspeciˆcity recognized only TEC in vitro, and when injected into the Colon26 bearing mice, this clone accumulated more on the tumor tissue than the wild type phage. These results suggest that the isolated an antibody and this clone's target molecule could be potentially useful for novel anti-tumor therapies.
The single chain antibody fragment variable (scFv) phage display library was prepared by amplifying the Fv genes from the mRNA derived from the TEC-immunized murine splenocytes. 
